Ute Hoch
FibroGen (United States)(US)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, Immune Cell Function and Interaction, Cancer therapeutics and mechanisms, CAR-T cell therapy research, Cancer Treatment and Pharmacology
Most-Cited Works
- → NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models(2016)387 cited
- → Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02)(2020)232 cited
- → A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors(2019)229 cited
- → Phase I and Pharmacologic Study of SNS-032, a Potent and Selective Cdk2, 7, and 9 Inhibitor, in Patients With Advanced Chronic Lymphocytic Leukemia and Multiple Myeloma(2010)216 cited
- → Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy(2020)166 cited
- → Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapy(2017)144 cited
- → SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples(2009)125 cited
- → Biotransformations with Peroxidases(1999)121 cited
- → Discovery of a potent and selective Aurora kinase inhibitor(2008)108 cited
- → Discovery and Development of Potent LFA-1/ICAM-1 Antagonist SAR 1118 as an Ophthalmic Solution for Treating Dry Eye(2012)96 cited